Posted On: 12/09/2015 6:16:35 PM
Post# of 30032
I have no idea what is going to happen if ANYTHING is going to happen at all. But looking at what ORAMED got from a Chinese pharma firm (50 million for a P2 Insulin Pill that I don't think will ever get approval) I have to think that ESS will get more based on the sought out dollar figure that Lonza was expecting from China to by out a "facility" along with the rights to manufacture Permaderm (AKA ESS). Note, ESS was to get immediate approval for commercial use in China had the deal gone through.
Per the legal document filed by Regenicin:
128. By the end of 2011, Lonza was negotiating to sell one of its biotech facilities to a
Chinese company for Seven Hundred Fifty Million Dollars ($750,000,000.00). However, the
Chinese company insisted that Lonza license to it the PermaDerm Know-How technology and
the marketing and distribution rights held by Regenicin.
129. Approval of PermaDerm for commercial use in China would have occurred
immediately upon or shortly after consummation of the Lonza biotech facility sale to the Chinese
company
http://www.regenicin.com/news/complaint_2013_09_30.pdf
What I am speculating is that the facility to be sold was where Permaderm was to be manufactured. That facility, again, was to be sold for $750,000,000. The Chinese wanted the a license to Permaderm as part of it. Why?
Now AMBS doesn't have a facility BUT they do have the rights to ESS which CHINA seemed to desperately want. We are about to find out if they truly still want it and give it a green light to be marketed and sold in China.
So if I am the CEO of AMBS, I am surely going to ask for a lot more than $50,000,000 for the rights to market and sell ESS in China.
Per the legal document filed by Regenicin:
128. By the end of 2011, Lonza was negotiating to sell one of its biotech facilities to a
Chinese company for Seven Hundred Fifty Million Dollars ($750,000,000.00). However, the
Chinese company insisted that Lonza license to it the PermaDerm Know-How technology and
the marketing and distribution rights held by Regenicin.
129. Approval of PermaDerm for commercial use in China would have occurred
immediately upon or shortly after consummation of the Lonza biotech facility sale to the Chinese
company
http://www.regenicin.com/news/complaint_2013_09_30.pdf
What I am speculating is that the facility to be sold was where Permaderm was to be manufactured. That facility, again, was to be sold for $750,000,000. The Chinese wanted the a license to Permaderm as part of it. Why?
Now AMBS doesn't have a facility BUT they do have the rights to ESS which CHINA seemed to desperately want. We are about to find out if they truly still want it and give it a green light to be marketed and sold in China.
So if I am the CEO of AMBS, I am surely going to ask for a lot more than $50,000,000 for the rights to market and sell ESS in China.
(0)
(0)Scroll down for more posts ▼
